Inventor · disambiguated record
Gregory Moore
Also filed as: MOORE GREGORY · MOORE GREGORY L
85 granted patents·72 pending applications·998 citations·filing 2002–2025
99Inventor score
Top patents by PatentIndex Score
157 records- 0199US12466897B2Heterodimeric human IgG1 polypeptides with isoelectric point modificationsXENCOR INC·Filed 2025·Granted Nov 11, 2025·1 cites·1 claims
- 0299US9605084B2Heterodimeric proteinsXENCOR INC·Filed 2014·Granted Mar 28, 2017·74 cites·16 claims
- 0398US10793632B2Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptorsXENCOR INC·Filed 2017·Granted Oct 6, 2020·22 cites·5 claims
- 0498US10428155B2Trispecific antibodiesXENCOR INC·Filed 2015·Granted Oct 1, 2019·39 cites·5 claims
- 0598US10259887B2Heterodimeric antibodies that bind CD3 and tumor antigensXENCOR INC·Filed 2016·Granted Apr 16, 2019·25 cites·25 claims
- 0698US10227410B2Heterodimeric antibodies that bind CD3 and PSMAXENCOR INC·Filed 2016·Granted Mar 12, 2019·36 cites·27 claims
- 0798US9856327B2Heterodimeric antibodies to CD3 X CD123XENCOR INC·Filed 2016·Granted Jan 2, 2018·72 cites·5 claims
- 0898US9701759B2Heterodimeric proteinsXENCOR INC·Filed 2014·Granted Jul 11, 2017·48 cites·8 claims
- 0998US9650446B2Heterodimeric proteinsXENCOR INC·Filed 2014·Granted May 16, 2017·44 cites·9 claims
- 1098US8362210B2Antibody variants with enhanced complement activityXENCOR INC·Filed 2011·Granted Jan 29, 2013·47 cites·10 claims
- 1198US8063187B2Methods and compositions for inhibiting CD32B expressing cellsCHU SEUNG YUP·Filed 2008·Granted Nov 22, 2011·130 cites·2 claims
- 1297US11591401B2Anti-CD28 compositionsXENCOR INC·Filed 2021·Granted Feb 28, 2023·19 cites·5 claims
- 1397US11472890B2Heterodimeric antibodies that bind ENPP3 and CD3XENCOR INC·Filed 2020·Granted Oct 18, 2022·9 cites·4 claims
- 1497US11225528B2Heterodimeric antibodies that bind CD3 and tumor antigensXENCOR INC·Filed 2019·Granted Jan 18, 2022·11 cites·13 claims
- 1597US10787518B2Bispecific checkpoint inhibitor antibodiesXENCOR INC·Filed 2017·Granted Sep 29, 2020·15 cites·19 claims
- 1697US10526417B2Heterodimeric antibodies that bind CD3 and CD38XENCOR INC·Filed 2015·Granted Jan 7, 2020·27 cites·15 claims
- 1796US11919958B2Anti-CD28 compositionsXENCOR INC·Filed 2021·Granted Mar 5, 2024·9 cites·16 claims
- 1896US11401348B2Heterodimeric Fc variantsXENCOR INC·Filed 2019·Granted Aug 2, 2022·10 cites·5 claims
- 1996US10738133B2Heterodimeric proteinsXENCOR INC·Filed 2017·Granted Aug 11, 2020·9 cites·7 claims
- 2096US9493578B2Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigensLAZAR GREGORY A·Filed 2010·Granted Nov 15, 2016·28 cites·10 claims
- 2196US9040041B2Modified FC moleculesDESJARLAIS JOHN R·Filed 2010·Granted May 26, 2015·35 cites·3 claims
- 2295US11623957B2Heterodimeric antibodies that bind CD3 and PSMAXENCOR INC·Filed 2016·Granted Apr 11, 2023·9 cites·28 claims
- 2395US11225521B2Heterodimeric antibodies that bind somatostatin receptor 2XENCOR INC·Filed 2019·Granted Jan 18, 2022·11 cites·23 claims
- 2495US11053316B2Optimized antibody variable regionsXENCOR INC·Filed 2018·Granted Jul 6, 2021·7 cites·6 claims
- 2595US10981992B2Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptorsXENCOR INC·Filed 2018·Granted Apr 20, 2021·6 cites·6 claims
- 2695US9850320B2Heterodimeric antibodies to CD3 X CD20XENCOR INC·Filed 2016·Granted Dec 26, 2017·13 cites·5 claims
- 2795US9822186B2Bispecific antibodies that bind to CD38 and CD3XENCOR INC·Filed 2015·Granted Nov 21, 2017·17 cites·16 claims
- 2895US9394366B2Methods and compositions for inhibiting CD32B expressing cellsCHU SEUNG YUP·Filed 2012·Granted Jul 19, 2016·16 cites·22 claims
- 2995US8314213B2Human equivalent monoclonal antibodies engineered from nonhuman variable regionsBERNETT MATTHEW J·Filed 2009·Granted Nov 20, 2012·36 cites·4 claims
- 3094US10131710B2Optimized antibody variable regionsXENCOR INC·Filed 2014·Granted Nov 20, 2018·15 cites·18 claims
- 3194US9079960B2Methods and compositions for inhibiting CD32B expressing cellsCHU SEUNG YUP·Filed 2012·Granted Jul 14, 2015·12 cites·16 claims
- 3293US11634506B2Heterodimeric proteinsXENCOR INC·Filed 2020·Granted Apr 25, 2023·2 cites·9 claims
- 3393US11530274B2Anti-STEAP1 antigen-binding proteinAMGEN INC·Filed 2019·Granted Dec 20, 2022·8 cites·72 claims
- 3493US10738132B2Heterodimeric proteinsXENCOR INC·Filed 2014·Granted Aug 11, 2020·9 cites·15 claims
- 3592US11945880B2Heterodimeric antibodies that bind CD3 and tumor antigensXENCOR INC·Filed 2021·Granted Apr 2, 2024·1 cites·13 claims
- 3692US11859011B2Heterodimeric antibodies that bind CD3 and tumor antigensXENCOR INC·Filed 2021·Granted Jan 2, 2024·1 cites·2 claims
- 3792US10316088B2Heterodimeric antibodies that bind somatostatin receptor 2XENCOR INC·Filed 2017·Granted Jun 11, 2019·11 cites·4 claims
- 3892US9260523B2Methods and compositions for inhibiting CD32b expressing cellsCHU SEUNG YUP·Filed 2011·Granted Feb 16, 2016·9 cites·1 claims
- 3992US7610156B2Methods for rational pegylation of proteinsXENCOR INC·Filed 2004·Granted Oct 27, 2009·29 cites·16 claims
- 4091US11299554B2Heterodimeric proteinsXENCOR INC·Filed 2019·Granted Apr 12, 2022·3 cites·10 claims
- 4191US10858417B2Heterodimeric proteinsXENCOR INC·Filed 2014·Granted Dec 8, 2020·7 cites·23 claims
- 4290US11618776B2Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domainsXENCOR INC·Filed 2019·Granted Apr 4, 2023·4 cites·7 claims
- 4390US9738722B2Rapid clearance of antigen complexes using novel antibodiesMOORE GREGORY L·Filed 2014·Granted Aug 22, 2017·13 cites·8 claims
- 4490US9475881B2Antibody variants with enhanced complement activityXENCOR INC·Filed 2013·Granted Oct 25, 2016·7 cites·6 claims
- 4589US11447552B2Methods and compositions for inhibiting CD32B expressing cellsCHU SEUNG YUP·Filed 2011·Granted Sep 20, 2022·3 cites·6 claims
- 4689US10106624B2Heterodimeric proteinsXENCOR INC·Filed 2014·Granted Oct 23, 2018·7 cites·6 claims
- 4788US12359002B2Heterodimeric antibodies that bind CD3 and tumor antigensXENCOR INC·Filed 2023·Granted Jul 15, 2025·0 cites·2 claims
- 4888US11739145B2Bispecific binding agents binding to CLDN18.2 and CD3ASTELLAS PHARMA EUROPE BV·Filed 2022·Granted Aug 29, 2023·1 cites·22 claims
- 4988US11352442B2Heterodimeric antibodies that bind CD3 and CD38XENCOR INC·Filed 2019·Granted Jun 7, 2022·2 cites·19 claims
- 5088US10968276B2Optimized anti-CD3 variable regionsXENCOR INC·Filed 2014·Granted Apr 6, 2021·6 cites·18 claims
Showing the top 50 of 157 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Gregory Moore files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →